This trial is evaluating whether Treatment will improve 1 primary outcome and 3 secondary outcomes in patients with Adenocarcinoma of Lung. Measurement will happen over the course of Every 3 months for 2 years.
This trial requires 100 total participants across 1 different treatment groups
This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Adenocarcinoma of the lung can originate from any of the various epithelial tissues in the lung. Adenocarcinoma of the lung is the tumor of most malignant potential. Most lung adenocarcinomas form in the lung tissue and metastasizes with time. There is a tendency for tumors to grow larger over time before metastasis. This is due to the tendency for carcinoma of the lung tissue to spread as it multiplies and grows in size. Adenocarcinoma of the lung accounts for the majority of lung cancer deaths. Adenocarcinoma in the lung has been shown to have the strongest effect on survival in cases of curative resection.
Recent findings highlighted several key points for the treatment of patients with lung adenocarcinoma. First, the treatment regime should be tailored to the clinical presentation, and consideration to exclude metastasis should be made. Second, lung adenocarcinoma can be cured by radical surgery, and adjuvant chemotherapy and radiotherapy offer some prolongation of survival.
Adenocarcinoma of lung does not seem to be one of the curable tumors under the best of present medical treatment. The cure rate is quite low for many tumors, including those with poor or no histologic differentiation. It will be important to define the subtype of adenocarcinoma of lung, using molecular markers, to predict the prognosis from a new perspective. We speculate that we need to improve our current treatment modalities for this subtype of lung cancer in the early stage so that more patients may have a better chance for cure.
Findings from a recent study suggests that there are approximately 250,000 new cases of lung cancer every year in the United States, with incidence in the majority of patients with adenocarcinoma (85%) as opposed to squamous cell (4.3% and 3.8% for adenocarcinoma and squamous cell, respectively).
Patients undergoing treatment of lung adenocarcinoma were typically treated in combination with surgical therapy in addition to radiotherapy and/or adjuvant agents, but most were treated in combination with systemic therapy, including chemotherapy. Use of non-systemic approaches was generally restricted to early-stage non-small-cell carcinoma patients, whereas systemic chemotherapy was used more often in patients with unresectable tumors. Clinicians are encouraged to consider using multimodal therapies in treating patients with lung adenocarcinoma because of the positive impact on local, regional, and distant recurrence, and survival.
Adenocarcinomas of the lung are highly lethal when diagnosed in the early stages. Lung Adenocarcinoma patients who have a higher percentage of tumour in the lower lobes, who reach a stage sooner after diagnosis, and who have more aggressive tumour types have a particularly high fatality rate. Further improvements in adjuvant chemotherapy and staging protocols are warranted in these high-risk patients.
Given the fact that we have no evidence of any treatment having better efficacy, the current practice of utilizing conventional chemotherapy as a first-line treatment option for most patients with advanced NSCLC may be inappropriate. Further research should be conducted to determine the most effective treatment method for such patients.
The current management for adenocarcinoma of lung comprises chemotherapy in combination with adjuvant radiation in adjuvant therapy for lymph node-positive disease and pN2+ primary tumor, as well as adjuvant radiation with concurrent chemotherapy for patients with pN2+ non-SLN metastasis and non-SLN involvement. As new treatments are developed, surgical resection in combination with post-operative chemotherapy should be considered for patients with resectable non-SLN involvement, pN2 disease, and non-SLN metastasis.
Nearly half of people diagnosed with adenocarcinoma of lung were not younger than age 75 years. There were no differences in age distribution for gender, race, ethnicity and marital status.
There is limited evidence of benefit of neoadjuvant therapy for Stage III non-small cell lung cancer. More work is needed to investigate this approach in order to improve its effectiveness. In a small pilot study, the use of pemetrexed in combination with cisplatin provided acceptable toxicity and disease control, which warrants further trial.